Chordia Therapeutics Inc. has announced that its CLK inhibitor, rogocekib, for treating Refractory or Relapsed Acute Myeloid Lymphoma (AML), has received Orphan Drug Designation from the FDA, offering developmental and financial benefits.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.